Systemic lupus erythematosus (SLE) Program in Pharmaceutical Benefits Scheme (PBS) 012-24060528

This document outlines details of PBS-subsidised anifrolumab for patients with systemic lupus erythematosus (SLE).

SLE and listing dates

SLE is a chronic autoimmune disease that can affect many parts of the body and cause inflammation and tissue damage.

Listing dates: anifrolumab - 1 July 2024.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

• application forms
• contact details
• restriction and item codes
• FAQs from Service Officers
• the PBS schedule
• Services Australia website link

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs